A sample obtained from routine Papanicolaou (Pap) tests used for cervical cancer screening can be subjected to a multiplex panel test, dubbed PapSEEK, to determine whether the sample is positive for endometrial or ovarian cancer, two gynecologic cancers for which early detection has been a problem.
The new test is described in a study published online March 21 in Science Translational Medicine.
"PapSEEK adds another dimension to screening for gynecologic cancers," write the authors, led by Yuxuan Wang of the Ludwig Center for Cancer Genetics and Therapeutics and the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland. Earlier this year, some of these researchers reported on the CancerSEEK test for eight common cancers, as reported by Medscape Medical News.
A graphic showing how the PapSEEK test detects tumor DNA. Tumor cells from ovarian or endometrial cancers are shed and are then carried into the uterine cavity and endocervical canal, where they can be collected with the Tao brush or the Pap brush.
The PapSEEK test includes a mutational analysis of 18 genes using a multiplex panel and an analysis for aneuploidy.
Using different approaches to collect the Pap sample, the test identified endometrial cancer in 81% to 93% of cases and ovarian cancer in 33% and 63% of cases, with nearly no false positive results (0 to 1.4%) in healthy control persons.
"Our study lays the foundation for evaluating PapSEEK in a large prospective study," Wang and colleagues write. They indicate that the most natural cohort for this test would be women who are at high risk for gynecologic cancers, owing to hereditary factors, obesity, or symptoms such as postmenopausal or uterine bleeding.
The utility of PapSEEK lies in its ability to identify difficult-to-detect endometrial and ovarian cancers at an early stage using a sample obtained from a routine Pap test, they comment. Current tests, such as transvaginal ultrasound, are invasive and result in many false positive results. Moreover, they are neither ideal nor recommended as a screening tool in the general population, Wang and colleagues point out.
Details of the PapSEEK Test
Wang and colleagues analyzed samples from 1658 individuals — 656 with endometrial or ovarian cancer, and 1002 healthy control persons.
They took advantage of the fact that endometrial and ovarian cancer cells collect in the endocervical canal, where they can be collected with a Pap brush. The brush is then dipped into a preservative fluid, and cells are applied to a slide for a cytologic examination of the classical Pap smear and for the PapSEEK test.
The researchers isolated DNA from the cells using a sensitive polymerase chain reaction (PCR) error-reduction technology called Safe-Sequencing System to identify mutations across 18 genes. They also determined aneuploidy using a PCR-based method to amplify ~30,000 loci to determine gains or losses on chromosomal arms.
They then used two separate methods to increase the sensitivity of the test. In one approach, they used a "Tao" brush that allows for interuterine sampling closer to the anatomic sites of the tumor. In the second approach, they undertook mutational analyses of circulating tumor DNA obtained from liquid biopsies.
Of the 328 women with endometrial cancer, 81% Pap brush samples tested positive. Of these, 78% were cases of early-stage cancer, and 89% were cases of late-stage disease. PTEN and TP53 were the most common mutations, seen in 64% and 41% of samples, respectively.
Of the 245 women with ovarian cancer, 29% Pap brush samples tested positive. Of these, 28% were cases of early-stage disease, and 30% were cases of late-stage disease. TP53 was the gene most frequently mutated (74%).
Wang and colleagues found aneuploidy in 38% of endometrial and 11% of ovarian Pap brush samples.
Taken together, the PapSEEK test from Pap brush samples detected endometrial and ovarian cancer in 81% and 33% of endometrial and ovarian cancers, respectively.
Of the 714 women without cancer, only 1.4% of samples were positive with the PapSEEK test, providing a high specificity of ~99%.
Tao brush samples were collected from 123 patients with endometrial cancer, 51 patients with ovarian cancer, and 125 women without cancer.
Using the PapSEEK test for Tao brush samples, the detection rate increased for both endometrial (93%) and ovarian cancer (45%). Mutations were consistent with those seen in Pap brush samples. Remarkably, none of Tao brush samples of the women without cancer tested positive — a specificity of 100%.
Eighty-three women with ovarian cancer had provided Pap brush samples and plasma samples. PapSEEK was positive for 40% of Pap brush samples; 43% of plasma samples showed mutations in circulating tumor DNA, with partial overlaps. Thus, using at least one of the two tests, 63% of samples tested positive for ovarian cancer.
Wang and colleagues note that large prospective studies are required to validate observations from this retrospective analysis.
These studies will need to answer several questions, the authors concede. Is Tao brush sampling superior to Pap brush sampling? The researchers explain that the Tao brush, which has been approved by the US Food and Drug Administration, allows sampling of the entire endometrial cavity without injury to the myometrium or contamination from the cervical canal. It can be used in the outpatient setting without anesthesia; "for a potential screening test, it is well tolerated," they comment.
Among the issues that need to be addressed is the question of whether PapSEEK would be used along with other approaches, such as serial CA-125 testing or liquid biopsies. Another question concerns the best clinical management of women who test positive with PapSEEK. Also unknown is the interval to use between tests.
The authors indicate that the cost of PapSEEK would be higher than that for a Pap smear; the cost would be comparable to that for colonoscopy, mammography, and CT imaging.
The researchers are optimistic, and their conclusion is upbeat. "PapSEEK adds another dimension to screening for gynecologic cancers," Wang and colleagues conclude.
Several authors receive a share of the royalties received by Johns Hopkins University. Several authors are cofounders of Personal Genome Diagnostics and PapGene Inc, which is commercializing advanced molecular tests for the early detection of cancers. PapGene Inc's proprietary next-generation DNA sequencing technology uses Safe-SeqS technology licensed from Johns Hopkins University; that technology was used in the study. Other relevant financial relationships are listed at the end of the original report.
Sci Transl Med. Published online March 21, 2018. Full text
Medscape Medical News © 2018
Cite this: PapSEEK: Potential Screening Test for Gynecologic Cancers - Medscape - Mar 21, 2018.